Gilead Science: Dominance in the HIV Market
Michael Kudrna submits:
Gilead Science (GILD) seemed to be on a roll lately, but has been met with a downgrade by the firm Morgan Joseph due to upcoming patent expiration concerns this decade. At the time of writing this, GILD was trading off its 52-week high to just under $48. At these levels, I feel GILD is undervalued as the pipeline is strong and the HIV sales will continue to be significant.
GILD has maintained dominance in the HIV market but, with patents expiring over the next decade, its HIV division is being threatened. Currently, 81% of GILD’s sales are from the HIV division so any threat of losing HIV sales would surely send GILD’s stock down. GILD plans to remedy those concerns with their new HIV drug Quad.
Investing, Long Term Investment, stock market | admin March 1, 2010
RSS feed for comments on this post.
